Details for Patent: 7,700,617

Title:	Salt of naphthyridine carboxylic acid derivative
Abstract:	A composition comprising 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and their use in antibacterial therapy.
Inventor(s):	Kim; Ae Ri (Daejeon, KR), Lee; Jin Hwa (Daejeon, KR), Park; Ki Sook (Daejeon, KR), Choi; Jong Ryoo (Daejeon, KR), Lee; Tae Hee (Daejeon, KR), Chang; Jay Hyok (Daejeon, KR), Nam; Do Hyun (Daejeon, KR), Choi; Hoon (Daejeon, KR)
Assignee:	LG Life Sciences, Ltd. (KR)
Filing Date:	Dec 07, 2006
Application Number:	11/635,069
Claims:	1. A method of treating a respiratory tract infection in a human or animal, comprising administering a therapeutically effective amount of a composition comprising 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and a pharmaceutically acceptable carrier or excipient to a human or animal with a respiratory tract infection. 2. A method of treating a urinary tract infection in a human or animal, comprising administering a therapeutically effective amount of a composition comprising 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-- oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and a pharmaceutically acceptable carrier or excipient to a human or animal with a urinary tract infection. 3. The method of claim 1, wherein the hydration number of the methanesulfonate hydrate is 1.5. 4. The method of claim 1, wherein the hydration number of the methanesulfonate hydrate is 3.0. 5. The method of claim 2, wherein the hydration number of the methanesulfonate hydrate is 1.5. 6. The method of claim 2, wherein the hydration number of the methanesulfonate hydrate is 3.0.